Company news

Kala Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders

June 9, 2020

Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease

May 25, 2020

Kala Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 6, 2020

Kala Pharmaceuticals Resubmits New Drug Application for EYSUVIS™ for Dry Eye Disease

May 3, 2020

Kala Pharmaceuticals Announces Exercise of Underwriters’ Option to Purchase Additional Shares

April 2, 2020

Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock

March 9, 2020

Kala Pharmaceuticals Announces Pricing of Public Offering of 16,000,000 Shares of Common Stock

March 9, 2020

Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS™ for Signs and Symptoms of Dry Eye Disease

March 8, 2020

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 11, 2020

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call

February 5, 2020

Kala Pharmaceuticals Announces Completion of Enrollment of STRIDE 3 Trial for EYSUVIS™ (KPI-121 0.25%) for Dry Eye Disease

January 14, 2020

Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 6, 2019

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.